Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Intensive BP Lowering, Yoga-Based Cardiac Rehab Highlighted Among Late-Breaking Science at AHA 2026Intensive blood-pressure (BP) lowering therapy in patients with type 2 diabetes and a yoga-based cardiac rehabilitation program for people with heart failure and reduced ejection fraction (HFrEF) were among the hot topics in cardiovascular prevention included in a late-breaking clinical science session at AHA 2026.
- STREAM, eZ-PAVE Add New Insights Into Statin Therapy TreatmentDiscontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years, according to findings from the STREAM trial presented at AHA 2026 and simultaneously published in NEJM.
- AHA 2026 Trials Examine Strategies to Improve Patient Care Post-StrokeFrom tackling blood clots to managing blood pressure (BP), three separate trials presented at AHA 2026 – REDUCE, OCEANIC-STROKE and OPTIMAL-STROKE – offer new insights into improving outcomes after stroke.
- Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a)Pelacarsen did not result in a lower risk of major adverse cardiovascular events compared with placebo in patients with preexisting cardiovascular disease and high lipoprotein(a) (Lp(a)) over a median follow-up period of approximately five years, based on findings from the Lp(a) HORIZON trial presented at AHA 2026 and simultaneously published in NEJM.
- ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic InflammationAnti-inflammatory therapy targeting interleukin-6 (IL-1β) with ziltivekimab (a monoclonal antibody) did not lower risks of cardiovascular events compared with placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and systemic inflammation, based on findings from the ZEUS trial presented at AHA 2026 and simultaneously published in NEJM.